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Abstract Background The anti-phospholipid syndrome (APS) is characterized by thrombosis
and/or pregnancy morbidity with persistent presence of anti-phospholipid antibodies
(aPL). Laboratory criteria include aPL detection by coagulation tests for lupus antic-
oagulant (LAC) or solid phase assays measuring anti-β2 glycoprotein I (aβ2GPI) or anti-
cardiolipin (aCL) immunoglobulin (Ig) G/IgM antibodies. External quality control
programs illustrate that commercially available aPL assays produce variable results.
Objective We aimed to investigate the agreement and diagnostic accuracy of solid
phase assays.
Materials and Methods In this multi-centre study, 1,168 patient samples were tested
on one site for aCL and aβ2GPI IgG/IgM antibodies by four solid phase test systems.
Samples included APS patients, controls and monoclonal antibodies (MoAB) against
different epitopes of β2GPI. LAC was determined by the local centre.
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Introduction
The anti-phospholipid syndrome (APS) is characterized by
thrombosis and/or pregnancy morbidity with the persistent
presence of anti-phospholipid antibodies (aPL).1 Laboratory
criteria include aPL detection by phospholipid-dependent
prolongation of coagulation tests referred to as lupus antic-
oagulant (LAC) or by solid phase assays measuring anti-β2
glycoprotein I (aβ2GPI) and anti-cardiolipin (aCL) immuno-
globulin (Ig) G/IgM antibodies.1 For the classiﬁcation of APS,
at least one clinical and one persistent positive laboratory
criterion is required.1 Given the high frequency of clinical
manifestations (thrombosis and pregnancy morbidity) asso-
ciated with APS in the general population, laboratory tests
are of utmost importance for the classiﬁcation of patients
with APS. Although LACpositivity is considered the strongest
predictor of clinical manifestations of APS, aCL and aβ2GPI
IgG/IgM antibodies have the same value in the current
classiﬁcation criteria.1–5
Anti-β2GPI antibodies are detected using β2GPI as antigen,
while both cardiolipin and β2GPI are used as antigens in aCL
immunoassays. The use of antigens from human sources is
preferred above antigens from animal origin (e.g. bovine) to
avoid false-positives.6 In contrast to aβ2GPI immunoassays,
antigens used in aCL immunoassays are not exclusively from
human origin (►Supplementary Table S1, available in the
online version). Traditionally, aCL and aβ2GPI antibodies are
detected with an enzyme-linked immunosorbent assay
(ELISA). Nowadays, more advanced and automated systems
have become available for the detection of aCL and aβ2GPI
aPL.7–10 Automated systems make use of an alternative solid
phase (e.g. magnetic beads) and use alternative detection
methods, such as chemiluminescence or (enzyme-linked)
ﬂuorescence. A large variety of assays are used in clinical
laboratories as there is no consensus on a ‘gold standard’ for
the detection of aCL and aβ2GPI aPL.6 Reports from external
quality control programs illustrate that aPL assays produce
variable results.11,12Detection of aβ2GPI antibodies is challen-
ging as some antibodies may be directed against a cryptic
epitope that is only exposed after conformational shape
change.13,14 Exposure of this cryptic epitope, spanning glycine
(Gly) 40-arginine (Arg) 43 in theﬁrstdomainofβ2GPI, has been
shown to vary across commercial aβ2GPI IgG assays.7,15 In
addition, variability between assays might be due to the
heterogeneous origin of aPL, differences in local working con-
ditions, differences in assay design and a lack of standardiza-
tion.6 As classiﬁcation of APS heavily depends on the detection
of aPL, variation within these tests will affect the treatment
strategy.
Therefore, we aimed to investigate the agreement and
diagnostic accuracy of commonly used commercially avail-
able solid phase assays measuring IgG and IgM aCL and
aβ2GPI aPL. Samples and normal pooled plasma supplemen-
ted with monoclonal antibodies (MoAB) against different
domains of β2GPI were tested with four assays at one
location by a single technician to exclude inter-laboratory
and inter-operator variation.
Materials and Methods
Patient Cohort
We obtained 1,168 samples from 8 European centres. Classi-
ﬁcationofAPSwasbasedontheSydneycriteria.1Patientswere
classiﬁed by the corresponding centre resulting in 259 throm-
botic APS patients (APS thrombosis), 204 patients with a
history of thrombosis and negative for laboratory criteria of
APS (non-APS thrombosis), 122 obstetric APS patients (APS
obstetric), 33 patients with pregnancy complications and
negative for laboratory criteria of APS (non-APS obstetric),
196 patients with an autoimmune disease other than APS
(autoimmune diseases), 100 individuals with a normal preg-
nancy (normal pregnancy), 194 controls that were referred for
aPL testing for other reasons than the clinical criteria of APS,
like subfertility and prolonged activated partial thromboplas-
tin time (controls) and 60 women that were diagnosed with
APS without information on the speciﬁcation of the clinical
manifestations (unspeciﬁed APS). Centres with the indicated
numberof samples includedGhent (469), London (196),Nîmes
(164), Nancy (114), Kraków (101), Milan (52), Geneva (50) and
Apeldoorn (22). The studywas approvedby the central and the
local ethical committees.
Results aCL IgM assays resulted in the most discrepancies (60%), while aCL IgG and
aβ2GPI IgM assays resulted in lower discrepancies (36%), suggesting better agreement.
Discrepant samples displayed lower median aPL titers. Dependent on the solid phase
test system, odds ratios (ORs) for thrombosis and pregnancy morbidity ranged from
1.98 to 2.56 and 3.42 to 4.78, respectively. Three platforms showed lower sensitivity
for MoAB directed against the glycine (Gly) 40-arginine (Arg) 43 epitope of domain I of
β2GPI.
Conclusion Poor agreement was observed between different commercially available
aCL and aβ2GPI IgG/IgM assays, hampering uniformity in the identiﬁcation of aPL-
positive patients. Clinical association was globally concordant between solid phase test
systems considering results of the four aPL together. An assay sensitive in detecting the
MoAB against Gly40-Arg43 of domain I of β2GPI reached the highest OR for thrombosis.
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Assays
aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM aPL were
measured in the Ghent University Hospital (Ghent, Belgium)
by four commercially available immunoassays: BioPlex2200
(Bio-Rad, Bio-Rad Laboratories, Hercules, California, United
States), ImmunoCapEliA (Thermo Fisher Scientiﬁc/Phadia,
Uppsala, Sweden), ACL AcuStar (Werfen/Instrumentation
Laboratories, Bedford, Massachusetts, United States) and
QUANTA Lite ELISA (Inova Diagnostics, San Diego, California,
United States) (►Supplementary Table S1, available in the
online version). Assays were selected based on frequently
used assays in the External quality Control of diagnostic
Assays and Tests program and the willingness of manufac-
turers for collaboration. Due to shortage of patient sample,
three and two patients were excluded for aCL IgG and aB2GPI
IgG detection by BioPlex2200, respectively. Manufacturers’
recommended cut-off valueswereusedupon conﬁrmation in
20 healthy volunteers, in accordance with the Scientiﬁc and
Standardization Committee (SSC) guidelines of the Interna-
tional Society on Thrombosis and Haemostasis.16 Assays
were performed according to the manufacturer’s instruc-
tions. All four methods were performed in parallel in runs
of 40 samples. According to the guidelines, single measure-
ment was used on the automated systems (BioPlex2200,
ImmunoCapEliA and ACL AcuStar) as the intra- and inter-
run imprecision coefﬁcientof variationwas < 10%anddupli-
cate measurement for the ELISA (QUANTA Lite ELISA).16 aPL
titers were expressed in arbitrary units (gram per litre, IgM
antiphospholipid units [MPL], U/mL, Standard IgG unit and
Standard IgM unit [SMU]). All samples weremeasured by the
same technician and values below the calculated limit of
detection (LOD) were replaced by the calculated LOD.
Monoclonal Antibodies
Twohuman-derivedMoAB P2–6 and P1–117were used to test
the speciﬁcity and sensitivity of the four commercially avail-
able aCL and aβ2GPI IgG assays. P2–6 recognizes β2GPI inde-
pendently of its conformation and P1–117 recognizes β2GPI in
its open conformation binding to the Gly40-Arg43 epitope of
the domain I.15,17 Serial dilutions of antibodies (0–250 µg/mL)
in normal pooled plasma were tested in duplicate for all
platforms included in thestudy. Platformswereusedaccording
to the manufacturer’s recommendations and these spiked
samples were handled as patient samples and tested in the
same conditions. The threshold for positivity corresponding to
a positive titer of aCL or aβ2GPI was determined.
Statistical Analysis
Solid phase assays were compared pairwise as no ‘gold stan-
dard’ for aPL detection exists. Agreement between assays in
positivity was assessed by 2  2 contingency tables in all
measured samples. Comparison of discrepancies between
aCL IgG, aCL IgM and aβ2GPI IgG and aβ2GPIgM positivity
was calculated: positivity discrepancy (%) ¼ (only positive for
methodA þ onlypositive formethodB) / (all positives)  100.
Median aPL titers within one platform were calculated with
titers above the cut-off value. Correlation between solid phase
assayswas performed bya Spearman’s rank correlation coefﬁ-
cient. Diagnostic accuracy was assessed by calculating odds
ratios (ORs), sensitivity, speciﬁcity, negative predictive value
(NPV), positive predictive value (PPV) and the receiver opera-
tor curve (ROC). The area under the ROC curve between solid
phase assays was compared using DeLong et al’s method.18
Signiﬁcance of differences was determined with the Mann–
WhitneyU test, as appropriate using the Statistical Package for
Social Sciences (SPSS 23.0; SPSS, Chicago, Illinois, United
States) and MedCalc Statistical Software version 17.7.2 (Med-
Calc Software bvba, Ostend, Belgium).
Results
We measured aCL IgG/IgM and aβ2GPI IgG/IgM aPL in 1,168
individuals with a mean age of 43 years ranging from 16 to
87yearsold (►Table 1)with fourcommerciallyavailable assays
(►Supplementary Table S1, available in the online version).
Laboratory criteria for the classiﬁcation of APS require at
least one positive aPL. We therefore compared positivity for
at least one aPL between platforms using 2  2 contingency
tables (►Table 2). Discrepancies varied between 79 (ACL
AcuStar vs. BioPlex2200) and 164 (ACL AcuStar vs. Immu-
noCapEliA) samples. aCL IgM and aβ2GPI IgG positivity
resulted in the most discrepancies, varying from 69 to 162
and 44 to 153 samples, respectively (►Table 3). On the other
hand, aCL IgG and aβ2GPI IgM positivity resulted in less
discrepancies between assays, varying from 49 to 98 and 34
to 58 samples, respectively. Comparison of discrepancies
between aCL IgG/IgM and aβ2GPI IgG/IgM positivity was
calculated by the percentage of discrepancies from all posi-
tives, resulting in a maximum discrepancy of 36, 60, 53 and
36% for aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM
positivity, respectively. In accordance, aCL IgM titers were
less correlated between the solid phase assays compared
with aCL IgG and aβ2GPI IgM with Spearman’s rank correla-
tion coefﬁcients of  0.514 (95% conﬁdence interval [CI],
0.471–0.555),  0.635 (95% CI, 0.599–0.668) and  0.738
(95% CI, 0.711–0.763), respectively (►Table 4).
aPL positive samples not in agreement across the plat-
forms were characterized by lower median aPL titers than
positives in agreement (►Fig. 1). However, for themajorityof
discrepancies observed, respective individuals suffered from
clinical manifestations of APS (thrombosis and/or pregnancy
morbidity) (►Fig. 1). Clinical implications of the observed
(dis)agreements were assessed by calculating the sensitivity,
speciﬁcity, NPV and PPV and OR for thrombosis, pregnancy
morbidity or both clinical criteria (►Table 5). Positivity was
deﬁnedwhen at least one aPLwas positive. Clinically affected
and non-clinically affected patients were set as outcome
variable rather than APS/non-APS to be independent of aPL
presence previously detected by the medical centres that
collected the samples, minimizing selection bias. Indepen-
dent from the assay used, a statistically signiﬁcant associa-
tion with thrombosis and/or pregnancy morbidity was
found. ORs for thrombosis varied between 1.98 (95% CI,
1.46–2.69) and 2.56 (95% CI, 1.82–3.59) detected by Immu-
noCapEliA and BioPlex2200, respectively. ORs for pregnancy
morbidity ranged between 3.42 (95% CI, 2.32–5.05) and 4.78
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(95% CI, 3.14–7.27) detected by ImmunoCapEliA and
QUANTA Lite ELISA, respectively. Although not the most
sensitive aPL detection platform for thrombosis and/or
pregnancy morbidity, the QUANTA Lite ELISA resulted in
the highest speciﬁcity (87.76% [95% CI, 84.52–90.52%]) and
OR (4.24 [95% CI, 3.10–5.79]). PPVs for thrombosis and/or
pregnancy morbidity ranged from 74.73% (95% CI, 70.74–
78.35%) to 80.77% (95% CI, 76.47–84.44%) and NPVs ranged
from49.71% (95%CI, 48.07–51.35%) to 50.23% (95%CI, 48.57–
51.90%) as shown in►Table 5. The area under the ROC curve
of the solid phase assays for thrombosis and/or pregnancy
morbidity was low as expected and was not signiﬁcantly
different among the tested solid phase assays.
BioPlex2200 aCL and aβ2GPI IgG showed the highest and
equal sensitivity for both MoAB P2–6, that recognizes β2GPI
independently of its conformation, and P1–117, which only
recognizes β2GPI upon exposure of the Gly40-Arg43 epitope
in domain I (►Table 6). ACL AcuStar aCL and aβ2GPI IgG
sensitivity was slightly lower for P1–117, in the same extent
for aCL and aβ2GPI. QUANTA Lite ELISA and ImmunoCapEliA
showed much lower sensitivity for P2–6 and P1–117, with
large difference in sensitivity for P2–6 and P1–117. Both aCL
assays did not detect P1–117 at all. OR for thrombosis and/or
pregnancy morbidity for aCL and aβ2GPI (►Table 5) ranged
from 4.24 to 6.12 and 3.49 to 6.56, respectively. The platform
(BioPlex2200) with the highest sensitivity in detecting the
P1–117 MoAB also reached the highest OR for thrombosis,
but not for pregnancy morbidity.
Discussion
APS classiﬁcation strongly depends on the laboratory criteria.
Besides the clinical criteria, thrombosis or pregnancymorbid-
ity, often due to other causes than aPL, APS is deﬁned by the
persistent presence of aPL.1 aPLs are detected by LAC assays or
by semi-quantitative solid phase assays measuring aCL IgG,
Table 1 Demographic and clinical characteristics of the study population
Patients
(n)
Female Age
[year, mean
(range)]
Pregnancy
morbidity
Thrombosis
Venous Arterial Venous
and
arterial
Small
vessel
Not
specified
APS thrombosis 259 164 (63%) 50 (17–87) 22 160 55 26 4 14
Non-APS
thrombosis
204 116 (57%) 46 (19–85) 0 149 47 5 0 3
APS obstetric 122 122 (100%) 35 (19–61) 122 4 2 0 0 4
Non-APS
obstetric
33 33 (100%) 33 (20–52) 33 NA NA NA NA NA
Autoimmune
diseases
196 158 (81%) 46 (16–83) NA NA NA NA NA NA
Normal
pregnancy
100 100 (100%) 31 (27–36) 0 NA NA NA NA NA
Controls 194 170 (88%) 39 (18–82) NA NA NA NA NA NA
Unspeciﬁed APS 60 60 (100%) 48 (24–70) NS NS NS NS NS NS
Total population 1,168 923 (79%) 43 (16–87) 177 313 104 31 4 21
Abbreviations: APS, anti-phospholipid syndrome; NA, not applicable; NS, not speciﬁed.
Table 2 Number of samples positive for aCL IgG, aCL IgM, aβ2GPI IgG or aβ2GPI IgM by BioPlex2200, ImmunoCapEliA, ACL AcuStar
and QUANTA Lite ELISA are compared pairwise
BioPlex 2200 ImmunoCap EliA ACL AcuStar
– þ – þ – þ
BioPlex 2200 –
þ
ImmunoCap EliA – 755 37
þ 108 268
ACL AcuStar – 795 11 717 89
þ 68 294 75 287
QUANTA Lite ELISA – 792 64 751 105 753 103
þ 71 241 41 271 53 259
Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti-β2 glycoprotein I; Ig, immunoglobulin.
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aCL IgM, aβ2GPI IgG or aβ2GPI IgM antibodies.1 Many studies
on head-to-head comparisons of solid phase assays with
different study designs, already have shown that solid phase
assays differ in performance and agreement. In our study, we
analysed a large cohort of APS and non-APS patients simulta-
neously with four different platforms, allowing comparison of
different methods on the same patient population. LAC was
determined by the local centre but excluded from the
Table 3 Discrepancies in aPL positivity detection between platforms
BioPlex 2200 ImmunoCap EliA ACL AcuStar
– þ – þ – þ
BioPlex 2200 –
þ
ImmunoCap EliA – 892 59
þ 25 190
ACL AcuStar – 905 37 913 30
þ 12 212 40 185
QUANTA Lite ELISA – 897 78 913 46 919 58
þ 20 171 22 169 24 167
BioPlex 2200 ImmunoCap EliA ACL AcuStar
– þ – þ – þ
BioPlex 2200 –
þ
ImmunoCap EliA – 895 69
þ 18 184
ACL AcuStar – 874 5 867 14
þ 39 248 99 188
QUANTA Lite ELISA – 909 115 964 62 877 149
þ 4 138 2 140 4 138
BioPlex 2200 ImmunoCap EliA ACL AcuStar
– þ – þ – þ
BioPlex 2200 –
þ
ImmunoCap EliA – 930 28
þ 119 91
ACL AcuStar – 989 9 897 101
þ 60 110 61 109
QUANTA Lite ELISA – 971 27 906 92 946 52
þ 78 92 52 118 52 118
BioPlex 2200 ImmunoCap EliA ACL AcuStar
– þ – þ – þ
BioPlex 2200 –
þ
ImmunoCap EliA – 1,007 23
þ 29 109
ACL AcuStar – 1,028 26 1,024 30
þ 8 106 6 108
QUANTA Lite ELISA – 997 19 996 20 1,006 10
þ 39 113 34 118 48 104
Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti-β2 glycoprotein I; aPL, anti-phospholipid antibodies; Ig, immunoglobulin.
Note: Number of samples positive for aCL IgG, aβ2GPI IgG, aCL IgM and aβ2GPI IgM by BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA Lite
ELISA are compared pairwise.
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Table 4 Correlation between aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgM titers of solid phase assays
aCL IgG
(95% CI)
aCL IgM
(95% CI)
aβ2GPI IgG
(95% CI)
aβ2GPI IgM
(95% CI)
BioPlex2200 vs. ImmunoCapEliA 0.712
(0.682–0.739)
0.514
(0.471–0.555)
0.784
(0.716–0.806)
0.739
(0.712–0.764)
BioPlex2200 vs. ACL AcuStar 0.767
(0.742–0.789)
0.803
(0.781–0.822)
0.900
(0.889–0.911)
0.813
(0.792–0.831)
BioPlex2200 vs. QUANTA Lite ELISA 0.744
(0.717–0.768)
0.586
(0.547–0.622)
0.676
(0.644–0.706)
0.701
(0.671–0.729)
ImmunoCapEliA vs. ACL AcuStar 0.635
(0.599–0.668)
0.521
(0.478–0.562)
0.758
(0.732–0.781)
0.775
(0.752–0.797)
ImmunoCapEliA vs. QUANTA Lite ELISA 0.716
(0.687–0.743)
0.562
(0.521–0.600)
0.686
(0.655–0.716)
0.764
(0.739–0.787)
ACL AcuStar vs. QUANTA Lite ELISA 0.673
(0.640–0.703)
0.580
(0.541–0.617)
0.632
(0.596–0.665)
0.738
(0.711–0.763)
Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti-β2 glycoprotein I; CI, Conﬁdence interval; Ig, immunoglobulin.
Note: Spearman Rank Correlation rho coefﬁcients with their respective 95% conﬁdence intervals are shown
Fig. 1 Anti-phospholipid antibodies (aPL) titers of samples in (dis)agreement. Titers of samples positive for all assays and assay discrepancies are shown as
detected with (A) BioPlex2200, (B) ImmunoCapEliA, (C) ACL AcuStar and (D) QUANTA Lite ELISA. Patients with thrombosis and/or pregnancy morbidity are
indicated in black andwithout in red. Titers are expressedas themedian value of positive aPL titerswith interquartile ranges. p < 0.001. AU, arbitrary units.
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comparative analysis to investigate the variation solely intro-
ducedby solidphaseassays. aPLs have a lowprevalence (1–5%)
in the general population, and APS is even more infrequent
(40–50/100,000 persons).19,20As a consequence, studies com-
paring aPL detection methods are often based on a small
patient groupand/or lackdiagnostic accuracy.We investigated
the (dis)agreement and diagnostic accuracy of four commer-
cially available solid phase assays for the detection of aCL IgG,
aCL IgM, aβ2GPI IgG and aβ2GPI IgM antibodies in 1,168
samples from eight European centres.
As in the Sydney criteria, all individual aPL are part of the
laboratorycriteria forAPS,diagnosticaccuracywasassessed for
positivity for at least one aPL detected by a solid phase assay
(aCL IgG, aCL IgM, aβ2GPI IgG or aβ2GPI IgM).1 Positivity for at
least one aPL detected by a solid phase assay was signiﬁcantly
correlatedwith thrombosis and/or pregnancymorbidity, inde-
pendent from the solid phase assay used. The highest OR for
thrombosis was obtained by detection of aPL by BioPlex2200
(2.56 [95% CI, 1.82–3.59]). Detection of aPL by ImmunoCapEliA
resulted in the lowest OR (1.98 [95% CI, 1.46–2.69]), mainly
because of lower speciﬁcity. aPL detection by BioPlex2200 and
QUANTA Lite ELISA resulted in similar OR for thrombosis and/
or pregnancymorbidity, higher than OR obtained by detection
with ImmunoCapEliA and ACL AcuStar. Calculated sensitivity,
Table 5 Diagnostic accuracy of aPL detection by BioPlex2200, ImmunoCapEliA, ACL AcuStar and QUANTA Lite ELISA
Sensitivity
(%, 95% CI)
Specificity
(%, 95% CI)
PPV
(%, 95% CI)
NPV
(%, 95% CI)
Odds ratio
(95% CI)
AUCa
(95% CI)
Thrombosis BioPlex2200 31.32
(27.12–35.76)
84.87
(80.92–88.28)
71.08
(65.21–76.32)
51.00
(49.14–52.86)
2.56
(1.82–3.59)
0.58
(0.55–0.61)
N ¼ 853b ImmunoCapEliA 36.29
(31.90–40.85)
77.69
(73.23–81.73)
65.88
(60.75–70.66)
50.67
(48.5–52.84)
1.98
(1.46–2.69)
0.57
(0.54–0.60)
ACL AcuStar 35.85
(31.48–40.41)
79.74
(75.41–83.62)
67.76
(62.50–72.59)
51.15
(49.04–53.26)
2.20
(1.61–3.00)
0.58
(0.54–0.61)
QUANTA
Lite ELISA
31.10
(26.91–35.54)
84.62
(80.65–88.05)
70.59
(64.71–75.86)
50.85
(48.99–52.71)
2.48
(1.77–3.48)
0.58
(0.55–0.61)
Pregnancy
morbidity
BioPlex2200 38.06
(30.39–46.20)
87.55
(84.30–90.34)
49.17
(41.52–56.85)
81.71
(79.73–83.55)
4.32
(2.84–6.58)
0.63
(0.59–0.67)
N ¼ 645c ImmunoCapEliA 45.16
(37.17–53.35)
80.61
(76.83–84.02)
42.42
(36.45–48.63)
82.29
(80.01–84.36)
3.42
(2.32–5.05)
0.63
(0.59–0.67)
ACL AcuStar 42.58
(34.68–50.77)
82.45
(78.79–85.71)
43.42
(37.06–50.01)
81.95
(79.76–83.95)
3.48
(2.35–5.17)
0.63
(0.59–0.66)
QUANTA
Lite ELISA
40.00
(32.22–48.17)
87.76
(84.52–90.52)
50.82
(43.22–58.38)
82.22
(80.19–84.08)
4.78
(3.14–7.27)
0.64
(0.60–0.68)
Clinical
criteria
BioPlex2200 35.99
(32.37–39.73)
87.55
(84.30–90.34)
80.00
(75.60–83.78)
49.71
(48.07–51.35)
3.95
(2.90–5.39)
0.62
(0.59–0.65)
N ¼ 1,168 ImmunoCapEliA 41.45
(37.71–45.26)
80.61
(76.83–84.02)
74.73
(70.74–78.35)
49.87
(47.96–51.79)
2.94
(2.24–3.86)
0.61
(0.59–0.65)
ACL AcuStar 40.71
(36.98–44.51)
82.45
(78.79–85.71)
76.24
(72.19–79.87)
50.12
(48.26–51.99)
3.23
(2.44–4.26)
0.62
(0.59–0.64)
QUANTA
Lite ELISA
37.17
(33.52–40.93)
87.76
(84.52–90.52)
80.77
(76.47–84.44)
50.23
(48.57–51.90)
4.24
(3.10–5.79)
0.63
(0.60–0.65)
Abbreviations: aPL, anti-phospholipid antibodies; APS, anti-phospholipid syndrome; AUC, area under the curve; CI, conﬁdence interval; LAC, lupus
anticoagulant; NPV, negative predictive value; PPV, positive predictive value.
Note: Samples were deﬁned as positive if at least one aPL was positive, excluding LAC.
aAUC from the receiver operator curve (ROC) were not signiﬁcantly different between solid phase assays.
bAPS thrombosis þ non-APS thrombosis þ AID þ controls.
cAPS obstetric þ non-APS obstetric þ AID þ normal pregnancy þ controls.
Table 6 Threshold for positivity: titer of MoAB corresponding to a positive titer of aCL or aβ2GPI IgG
aCL IgG aβ2GPI IgG
BioPlex
2200
ImmunoCap
EliA
ACL
AcuStar
QUANTA
Lite ELISA
BioPlex
2200
ImmunoCap
EliA
ACL
AcuStar
QUANTA
Lite ELISA
P2–6 (µg/mL) 1.95 125 15.63 62.5 1.95 31.25 1.95 62.5
P1–117 (µg/mL) 1.95 Nega 31.25 Nega 1.95 125 7.81 125
Abbreviations: aCL, anti-cardiolipin; aβ2GPI, anti-β2 glycoprotein I; Ig, immunoglobulin; MoAB, monoclonal antibodies.
aNegative results for all concentrations.
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NPVandAUC for thrombosis and/or pregnancymorbiditywere
low as expected, since we included patients with thrombosis
and/or pregnancy morbidity without APS (negative for aPL).
Inclusion of only APS patients would lead to a selection bias as
diagnosis of APS is dependent on the aPL detection assays used
by the local centre.
In our study, a maximum discrepancy of 36, 60, 53 and 36%
for aCL IgG, aCL IgM, aβ2GPI IgG and aβ2GPI IgMpositivitywas
found, respectively. Detection of aCL IgG and aβ2GPI IgM
resulted in the best agreement. However, still a substantial
number of samples were in disagreement. Conversely, a study
comparing different kits detecting aCL and aβ2GPI IgG/IgM
found better agreement between aβ2GPI ELISAs than aCL
ELISAs.21 This might be a consequence of the small number
of aβ2GPI positive samples in this study.21 Another study
compared the performance of aCL IgG and IgM antibody
detectionof the ImmunoCapEliAwith their in-houseaCLELISA
in 1,143 routine samples.22 The authors reached a good
agreement (> 90%) between the automated systems and their
in-house ELISA.22 As expected, positivity for aPL proved to be
relatively rare, because of which the majority of routine
samples were classiﬁed as negative, independent of the
method used, resulting in a high agreement. Importantly,
more sampleswere classiﬁedpositivebyonly ImmunoCapEliA
or only the in-houseELISA thanbybothmethods (116/179and
72/90 for aCL IgG and aCL IgM, respectively), suggesting a poor
agreement comparable to our ﬁndings.22 We observed large
differences in positivity across platforms, even between auto-
mated systems sharing the same solid phase (BioPlex2200 vs.
ACL AcuStar). In a collaborative study, the inter-laboratory
variability of aβ2GPI IgG and aβ2GPI IgM antibodies was
assessed in 30 serum samples from 22 centres.23 Poor agree-
ment was found between centres as positivity ranged from 50
to 93% and 13 to 70% for aβ2GPI IgG and aβ2GPI IgMdetection,
respectively.23 We excluded inter-laboratory variability and
found the best agreement between BioPlex2200 and ACL
AcuStar. However, OR for clinical features of APS obtained by
BioPlex2200 were more comparable with an ELISA (QUANTA
Lite ELISA) than an assay sharing the same solid phase (ACL
AcuStar). BioPlex2200 and QUANTA Lite ELISA were in poor
agreement but characterized by a comparable diagnostic
accuracy. Our results highlight the importance of measuring
both the agreement between assays aswell as their diagnostic
accuracy. It seemsalso important that in daily practice the four
aPLs aremeasuredwith a sameplatform.Although somesmall
differences exist in the diagnostic performance of the tested
platforms, the values of sensitivity and speciﬁcity for APS-
related clinical symptoms and OR for clinical events are
essentially comparable. This may be explained by the higher
agreement that was observed in samples with higher levels of
aPL (►Fig. 1). That newer generation ELISA and automated
systems show low agreement but comparable diagnostic
accuracy was also illustrated in other studies.9,10,24–26
In our study, guidelines from the SSC were followed by
conﬁrming manufacturer’s cut-off values in at least 20
healthy volunteers.16 In practice, most laboratories transfer
their cut-off values similarly, predominately due to practical
difﬁculties to calculate the 99th percentiles in a population
of at least 120 healthy volunteers. Positivity for aPL not in
agreement across the assays were characterized by lower
median aPL titers. The majority of samples positive for aCL
and/or aβ2GPI IgG/IgM detected by one assay, but not for all
solid phase assays, fulﬁlled the clinical criteria of APS,
suggesting that higher cut-off values result in reduced sen-
sitivity for APS. The clinical relevance of aPL levels below the
99th percentile, needs to be further studied.27 Lower levels of
antibodies are observed especially in obstetric APS.28,29
Variability between aPL detecting assays is hypothesized to
result from pre-analytical, analytical and post-analytical con-
ditions, calibration and assay-speciﬁc issues.30,31 In our study,
detection of aPL and analysis was performed by a single
operator, eliminating inter-laboratory and inter-operator var-
iation. Traditionally, aCL andaβ2GPI antibodiesaredetectedby
ELISAs. Nowadays, automated systems have become available
which are hypothesized to improve agreement.8 Automation
of assays indeed improved intra-laboratory and inter-labora-
tory reproducibility compared with non-automated ELISA. In
general, ELISAs have shown large inter-laboratory variation
and limited consensus in external quality control pro-
grams.11,12 The lack of international calibration standards
makes the comparison between assays challenging. Efforts
havebeenmade for standardizationby international reference
materials, such as the Harris standards (pool of patient mate-
rial and thus limited in production) and Koike standards
(directed against a single epitope, thus decreasing the sensi-
tivity of the assay in which it is used as aPL), although not
reﬂecting the real life since aPL ofpatients are aheterogeneous
group of antibodies.31 Variation in aPL detection might be
introduced by the heterogeneous origin of aPL, differences in
assay design and a lack of standardization. All four tested
aβ2GPI antibody detection assays make use of an antigen of
human origin. However, for detection of aCL antibodies only
BioPlex2200 uses human β2GPI and non-animal derived car-
diolipin. Human antigen source is considered more speciﬁc
than animal CL and/or β2GPI.6 Different preparations of
human β2GPI have shown not to inﬂuence agreement in
aβ2GPI IgG and IgM detection.32 Indeed, BioPlex2200 and
QUANTA Lite ELISA showed high speciﬁcity for thrombosis
and/or pregnancy morbidity. However, our results show that
the QUANTA Lite ELISA using puriﬁed cardiolipin and bovine
β2GPI as antigen source resulted in the highest speciﬁcity for
thrombosis and/or pregnancy morbidity.
Anti-β2GPI immunoassays detect antibodies against all ﬁve
domains of β2GPI, including non-pathogenic antibodies, phos-
pholipid-independent and low afﬁnity aβ2GPI.6,33 The use of
negative surface chargeof thesolidphase inaβ2GPIELISAshave
shown to increase the antigen density and exposure of cryptic
epitopes of β2GPI such as Gly40-Arg43 in domain I, mimicking
the binding between negatively charged phospholipids and
β2GPI.6,13,14 Variation in solid phase may lead to variability in
exposure of the epitope Gly40-Arg43.15 Hence, antibodies
against the Gly40-Arg43 epitope are considered pathogenic
andhave shown to highly correlatewith thrombosis.13,14,34We
used patient-derived MoAB P1–117 and P2–6 to verify and
assess variability in exposure of epitopes of β2GPI.7,15,17 We
conﬁrmedthat theplatformmostsensitive indetectingP1–117
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(the MoAB reactive against Gly40-Arg43 in domain I) by both
the aCL and aβ2GPI IgG assays has the highest OR for throm-
bosis. Other platforms are less sensitive in detecting P1–117
comparedwith P2–6 (theMoAB recognizingβ2GPI irrespective
of its conformation), resulting in lower OR for thrombosis.
In conclusion, we found poor agreement between com-
mercially available immunoassays detecting aCL and aβ2GPI
IgG/IgM antibodies, which may hamper uniformity in the
classiﬁcation of aPL positive samples. However, computed
OR for thrombosis and/or pregnancy morbidity in our study,
considering results of the four aPL together, were globally
concordant among solid phase test systems. Since our com-
parison between systems is based on considering measure-
ment of the four aPL within one test system, classiﬁcation
and follow-up of patients for aPL is preferable when per-
formed with the same system.
What is known about this topic?
• Detection of anti-phospholipid antibodies by solid
phase assays is poorly standardized.
• Detection of patients positive for anti-cardiolipin and
anti-β2GPI antibodies is assay dependent.
What does this paper add?
• Solid phase assays show comparable association for
thrombosis and pregnancy morbidity.
• Exposure of Gly40-Arg43 of β2GPI in commercial
assays is important to detect thrombotic APS.
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